Objective To investigate the efficacy and risk factors of Bacillus Calmette-Guérin(BCG)perfusion therapy after tran-surethral resection of bladder tumors(TURBT)in primary and recurrent non-muscle invasive bladder cancer(NMIBC).Methods The clinicopathological and follow-up data of 122 patients with NMIBC infused with BCG vaccine after TURBT in the Second Hospital of Lanzhou University from May 2016 to December 2021 were retrospectively analyzed,and the patients were divided into the primary group(n=79)and recurrent group(n=43)according to the type of onset of the disease,and the clinicopathological characteristics of the two groups were compared,including gender,age,number of tumors,pathological stage,pathological grade,and preoperative inflammation index[systemic immune inflammation index(SII),neutrophil-to-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR),monocyte-to-lymphocyte ratio(MLR)].Univariate COX regression analysis was used to evaluate the risk factors associated with tumor recurrence,and Kaplan-Meier was used for survival difference analysis.Results The results of Univariate COX regression analysis showed that pathological stage and grade were risk factors affecting the failure of BCG perfusion therapy in patients with recurrent bladder cancer(P＜0.05).The results of Kaplan-Meier survival analysis showed that the risk of recurrence of stage T1,high-grade and high-grade T1 tumors in the recurrence group was significantly higher than that in the primary group(P＜0.05),and the risk of recur-rence of high-grade T1 tumors in the recurrence group was significantly higher than that of other tumors(P＜0.05).Conclusion Path-ological stage and grade are risk factors for failure of BCG perfusion therapy for recurrent NMIBC.The recurrence rate of BCG perfusion therapy for recurrent high-grade T1 NMIBC is significantly higher than non-recurrent high-grade T1 stage tumors.Therefore,BCG per-fusion therapy should be chosen carefully for the treatment of recurrent high-grade T1 stage NMIBC,with the option of radical cystectomy if necessary.

Objective To investigate the efficacy and risk factors of Bacillus Calmette-Guérin(BCG)perfusion therapy after tran-surethral resection of bladder tumors(TURBT)in primary and recurrent non-muscle invasive bladder cancer(NMIBC).Methods The clinicopathological and follow-up data of 122 patients with NMIBC infused with BCG vaccine after TURBT in the Second Hospital of Lanzhou University from May 2016 to December 2021 were retrospectively analyzed,and the patients were divided into the primary group(n=79)and recurrent group(n=43)according to the type of onset of the disease,and the clinicopathological characteristics of the two groups were compared,including gender,age,number of tumors,pathological stage,pathological grade,and preoperative inflammation index[systemic immune inflammation index(SII),neutrophil-to-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR),monocyte-to-lymphocyte ratio(MLR)].Univariate COX regression analysis was used to evaluate the risk factors associated with tumor recurrence,and Kaplan-Meier was used for survival difference analysis.Results The results of Univariate COX regression analysis showed that pathological stage and grade were risk factors affecting the failure of BCG perfusion therapy in patients with recurrent bladder cancer(P＜0.05).The results of Kaplan-Meier survival analysis showed that the risk of recurrence of stage T1,high-grade and high-grade T1 tumors in the recurrence group was significantly higher than that in the primary group(P＜0.05),and the risk of recur-rence of high-grade T1 tumors in the recurrence group was significantly higher than that of other tumors(P＜0.05).Conclusion Path-ological stage and grade are risk factors for failure of BCG perfusion therapy for recurrent NMIBC.The recurrence rate of BCG perfusion therapy for recurrent high-grade T1 NMIBC is significantly higher than non-recurrent high-grade T1 stage tumors.Therefore,BCG per-fusion therapy should be chosen carefully for the treatment of recurrent high-grade T1 stage NMIBC,with the option of radical cystectomy if necessary.